---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-25-000069"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:21:29.934422+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Centessa Q1 net loss $26.1M; cash $424.9M; OX2R agonist pipeline on track for 2025 data

## Summary
- Net loss narrowed to $26.1M from $38.0M in Q1 2024, with no product revenue.
- Cash, equivalents and investments totaled $424.9M, expected to fund operations into mid-2027.
- R&D expenses increased to $33.4M from $22.7M, driven by pipeline advancement.
- ORX750 Phase 2a CRYSTAL-1 study ongoing; data from narcolepsy NT1, NT2 and IH anticipated in 2025.
- ORX142 first-in-human studies planned in 2025 with data from sleep-deprived healthy volunteers expected.

## SEC filing metadata
- accession: 0001847903-25-000069
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000069/0001847903-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790325000069/cnta-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-25-000069
- JSON: https://secwatch.observer/filing/0001847903-25-000069.json
- Plain text: https://secwatch.observer/filing/0001847903-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.